Metacrine, Inc. (MTCR)
Stock Price:
$10.10 USD
0.05 (0.50%)
Updated Sep 18, 2020 4:00 PM EDT - Market closed
After-hours: $10.05 -0.05 (-0.50%) Sep 18, 7:31 PM
Key Info
| Market Cap |
195.76M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-33.30M |
| Shares Out |
19.38M |
| EPS (ttm) |
-1.28 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Sep 18, 2020 |
| Last Price |
$10.10 |
| Previous Close |
$10.05 |
| Change ($) |
0.05 |
| Change (%) |
0.50% |
| Day's Open |
10.00 |
| Day's Range |
10.00 - 10.29 |
| Day's Volume |
219,456 |
| 52-Week Range |
10.00 - 16.19 |
More Stats
| Market Cap |
195.76M |
| Enterprise Value |
167.79M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
19.38M |
| Float |
6.18M |
| EPS (basic) |
n/a |
| EPS (diluted) |
-1.28 |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
n/a |
| Short Ratio |
n/a |
| Short % of Float |
n/a |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
n/a |
| Revenue |
n/a |
| Operating Income |
n/a |
| Net Income |
-33.30M |
| Free Cash Flow |
n/a |
| Net Cash |
27.97M |
| Net Cash / Share |
1.44 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
n/a |
| ROE |
n/a |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
*No analysts have provided price targets for this stock.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | - | 1.45 |
| Gross Profit | - | 1.45 |
| Operating Income | -30.00 | -26.73 |
| Net Income | -28.93 | -25.82 |
| Shares Outstanding | 2.38 | 2.09 |
| Earnings Per Share | -12.17 | -12.35 |
| Operating Cash Flow | -27.75 | -25.48 |
| Capital Expenditures | -0.08 | -0.68 |
| Free Cash Flow | -27.83 | -26.16 |
| Cash & Equivalents | 55.65 | 72.99 |
| Total Debt | 11.45 | 2.85 |
| Net Cash / Debt | 44.20 | 70.13 |
| Assets | 60.28 | 77.80 |
| Liabilities | 139 | 129 |
| Book Value | -78.24 | -51.47 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Metacrine, Inc. |
| Country |
United States |
| Employees |
32 |
| CEO |
Preston S. Klassen |
Stock Information
| Ticker Symbol |
MTCR |
| Stock Exchange |
NASDAQ |
| Sector |
Health Technology |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: MTCR |
| IPO Date |
September 16, 2020 |
Description
Metacrine, Inc. is a clinical-stage biopharmaceutical company that engages in the discovery and development of differentiated therapies for patients with liver and gastrointestinal diseases. Its farnesoid X receptor, or FXR, is central to modulating liver and GI diseases. The company was founded by Ronald M. Evans, Richard A. Heyman, and Michael Downes in 2014 and is headquartered in San Diego, CA.